Pure Global AI
NCT06379087Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Prospective Phase II Study of Hypofractionated Radiotherapy Sequential Tislelizumab and Anlotinib in the Neoadjuvant and Adjuvant Therapy for Stage II-IIIA Non-Small Cell Lung Cancer
Ji YonglingPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
Anlotinib Hydrochloride Capsule
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ji Yongling
Funder
Zhejiang Cancer Hospital
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Dec 31, 2026
Enrollment
20 participants
Primary outcome

1-year EFS Rate

Summary

This study is a single-center, prospective, single-arm exploratory clinical study of
 hypofractionated radiotherapy followed by tislelizumab and anlotinib neoadjuvant and adjuvant
 therapy. It is designed for patients with stage II-IIIA non-small cell lung cancer. The
 efficacy and safety of hypofractionated radiotherapy sequential tislelizumab and anlotinib in
 the neoadjuvant and adjuvant treatment of stage II-IIIA non-small cell lung cancer are
 observed. Finally, it provides new evidence-based medical evidence for the perioperative
 treatment of non-small cell lung cancer.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06379087
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06379087 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ji Yongling and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.